Correction: A mathematical model of multisite phosphorylation of tau protein (PLoS ONE (2018) 13:2 (e0192519) DOI: 10.1371/journal.pone.0192519);A mathematical model of multisite phosphorylation of tau protein

PLoS ONE

Volumn 13, Issue 2, 2018, Pages

  Stepanov, Alexander ^a   Karelina, Tatiana ^a   Markevich, Nikolai ^a,c   Demin, Oleg ^a   Nicholas, Timothy ^b  

^a InSysBio   (Russian Federation)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE;

ARTICLE; KINETICS; MATHEMATICAL MODEL; PROBABILITY; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIMULATION; STOICHIOMETRY; ALZHEIMER DISEASE; HUMAN; METABOLISM; PHOSPHORYLATION; TAUOPATHY; THEORETICAL MODEL;

ALZHEIMER DISEASE; HUMANS; MODELS, THEORETICAL; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PHOSPHATASE 2; TAU PROTEINS; TAUOPATHIES;

EID: 85041400134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0194002     Document Type: Erratum

References (41)

1. Cleveland DW, Hwo S-Y, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol. 1977; 116: 207–225. https://doi.org/10.1016/0022-2836(77)90213-3 PMID: 599557
2. Flores-Rodríguez P, Ontiveros-Torres MA, Cárdenas-Aguayo MC, Luna-Arias JP, Meraz-Ríos MA, Vir-amontes-Pintos A, et al. The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer’s disease. Front Neurosci. 2015; 9: 33. https://doi.org/10.3389/fnins.2015.00033 PMID: 25717290
3. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009; 15: 112–9. https://doi.org/10.1016/j.molmed.2009.01.003 PMID: 19246243
4. BILLINGSLEY ML, KINCAID RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J. 1997; 323: 577–591. https://doi.org/10.1042/bj3230577 PMID: 9169588
5. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem. 1997; 167: 99–105. https://doi.org/10.1023/A:1006883924775 PMID: 9059986
6. Leroy A, Landrieu I, Huvent I, Legrand D, Codeville B, Wieruszeski J-M, et al. Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem. 2010; 285: 33435–44. https://doi.org/10.1074/jbc.M110.149419PMID: 20679343
7. Medina M, Wandosell F. Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis. 2011; 2011: 479249. https://doi.org/10.4061/2011/479249 PMID: 21629747
8. Jin N, Wu Y, Xu W, Gong C-X, Iqbal K, Liu F. C-terminal truncation of GSK-3? enhances its dephosphorylation by PP2A. FEBS Lett. 2017; 591: 1053–1063. https://doi.org/10.1002/1873-3468.12617PMID: 28267204
9. Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-? toxicity in Alzheimer’s mice. Science (80-). 2016; 354: 904–908. https://doi.org/10.1126/science.aah6205 PMID: 27856911
10. Liu F, Grundke-Iqbal I, Iqbal K, Gong C-X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005; 22: 1942–50. https://doi.org/10.1111/j.1460-9568.2005.04391.x PMID: 16262633
11. Khanna MR, Kovalevich J, Lee VM-Y, Trojanowski JQ, Brunden KR. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer’s Dement. 2016; 12: 1051–1065. https://doi.org/10.1016/j.jalz.2016.06.006 PMID: 27751442
12. Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline: 2016. Alzheimer’s Dement Transl Res Clin Interv. 2016; 2: 222–232. https://doi.org/10.1016/j.trci.2016.07.001 PMID: 29067309
13. Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MWC, Al-Ramahi I, et al. Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron. Elsevier Inc.; 2016; 92: 407–418. https://doi.org/10.1016/j.neuron.2016.09.022 PMID: 27720485
14. Suwanmajo T, Krishnan J. Mixed mechanisms of multi-site phosphorylation. J R Soc Interface. 2015; 12: 20141405–20141405. https://doi.org/10.1098/rsif.2014.1405 PMID: 25972433
15. Danos V, Feret J, Fontana W, Harmer R, Krivine J. Rule-Based Modelling of Cellular Signalling. CONCUR 2007 –Concurrency Theory. Berlin, Heidelberg: Springer Berlin Heidelberg; pp. 17–41. https://doi.org/10.1007/978-3-540-74407-8_3
16. Danos V, Laneve C. Formal molecular biology. Theor Comput Sci. 2004; 325: 69–110. https://doi.org/10.1016/j.tcs.2004.03.065
17. Faeder JR, Blinov ML, Goldstein B, Hlavacek WS. Combinatorial complexity and dynamical restriction of network flows in signal transduction. Syst Biol (Stevenage). 2005; 2: 5–15. Available: http://www.ncbi.nlm.nih.gov/pubmed/17091578
18. Borisov NM, Markevich NI, Hoek JB, Kholodenko BN. Signaling through receptors and scaffolds: independent interactions reduce combinatorial complexity. Biophys J. 2005; 89: 951–66. https://doi.org/10.1529/biophysj.105.060533 PMID: 15923229
19. Salazar C, Höfer T. Multisite protein phosphorylation—from molecular mechanisms to kinetic models. FEBS J. 2009; 276: 3177–98. https://doi.org/10.1111/j.1742-4658.2009.07027.x PMID: 19438722
20. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, et al. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett. 2006; 580: 6269–74. https://doi.org/10.1016/j.febslet.2006.10.033 PMID: 17078951
21. Godemann R, Biernat J, Mandelkow E, Mandelkow E-M. Phosphorylation of tau protein by recombinant GSK-3?: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett. 1999; 454: 157–164. https://doi.org/10.1016/S0014-5793(99)00741-3PMID: 10413115
22. Gizzatkulov NM, Goryanin II, Metelkin EA, Mogilevskaya EA, Peskov K V, Demin O V. DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results. BMC Syst Biol. 2010; 4: 109. https://doi.org/10.1186/1752-0509-4-109 PMID: 20698988
23. Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y. Structure of a Protein Phosphatase 2A Holoenzyme: Insights into B55-Mediated Tau Dephosphorylation. Mol Cell. 2008; 31: 873–885. https://doi.org/10.1016/j.molcel.2008.08.006 PMID: 18922469
24. Kolobkov D, Demin O, Metelkin E. Comparison of asymptotic confidence sets for regression in small samples. J Biopharm Stat. 2016; 26: 742–57. https://doi.org/10.1080/10543406.2015.1052818 PMID: 26099035
25. Suwanmajo T, Krishnan J. Biphasic responses in multi-site phosphorylation systems. J R Soc Interface. 2013; 10: 20130742–20130742. https://doi.org/10.1098/rsif.2013.0742 PMID: 24108693
26. Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-? toxicity in Alzheimer’s mice. Science. 2016; 354: 2–66. https://doi.org/10.1126/science.aah6205 PMID: 27856911
27. Ding H, Matthews T a, Johnson GVW. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem. 2006; 281: 19107–14. https://doi.org/10.1074/jbc.M511697200 PMID: 16687396
28. Povellato G, Tuxworth RI, Hanger DP, Tear G. Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3?. Biol Open. 2014; 3: 1–11. https://doi.org/10.1242/bio. 20136692 PMID: 24429107
29. Kiris E, Ventimiglia D, Sargin ME, Gaylord MR, Altinok A, Rose K, et al. Combinatorial Tau Pseudopho-sphorylation: MARKEDLY DIFFERENT REGULATORY EFFECTS ON MICROTUBULE ASSEMBLY AND DYNAMIC INSTABILITY THAN THE SUM OF THE INDIVIDUAL PARTS. J Biol Chem. 2011; 286: 14257–14270. https://doi.org/10.1074/jbc.M111.219311 PMID: 21288907
30. Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T, et al. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3?. FEBS J. 2013; 1–11. https://doi.org/10.1111/febs.12579 PMID: 24165324
31. Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz H-J, et al. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis. 2015; 45: 75–88. https://doi.org/10.3233/JAD-141959 PMID: 25537011
32. Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin J-J, De Deyn PP, et al. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Front Neurol. 2015; 6: 1–8.
33. Ben Bouallègue F, Mariano-Goulart D, Payoux P. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther. Alzheimer’s Research & Therapy; 2017; 9: 32. https://doi.org/10.1186/ s13195-017-0260-z PMID: 28441967
34. Landrieu I, Leroy A, Smet-Nocca C, Huvent I, Amniai L, Hamdane M, et al. NMR spectroscopy of the neuronal tau protein: normal function and implication in Alzheimer’s disease. Biochem Soc Trans. 2010; 38: 1006–11. https://doi.org/10.1042/BST0381006 PMID: 20658994
35. Landrieu I, Lacosse L, Leroy A, Wieruszeski J, Trivelli X, Sillen A, et al. NMR analysis of a Tau phosphorylation pattern. J Am Chem Soc. 2006; 128: 3575–83. https://doi.org/10.1021/ja054656+ PMID: 16536530
36. Amniai L, Lippens G, Landrieu I. Characterization of the AT180 epitope of phosphorylated Tau protein by a combined nuclear magnetic resonance and fluorescence spectroscopy approach. Biochem Biophys Res Commun. 2011; 412: 743–6. https://doi.org/10.1016/j.bbrc.2011.08.046 PMID: 21871442
37. Wang Y, Yang R, Gu J, Yin X, Jin N, Xie S, et al. Cross talk between PI3K-AKT-GSK-3? and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging. 2015; 36: 188–200. https://doi.org/10.1016/j.neurobiolaging.2014.07.035 PMID: 25219467
38. Plattner F, Angelo M, Giese KP. The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation * ?. 2006; 281: 25457–25465. https://doi.org/10.1074/jbc. M603469200 PMID: 16803897
39. Chu D, Tan J, Xie S, Jin N, Yin X, Gong C-X, et al. GSK-3? is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. Wang J, editor. J Alzheimers Dis. 2016; 49: 365–75. https://doi.org/10.3233/JAD-150497 PMID: 26484916
40. Yao X-Q, Zhang X-X, Yin Y-Y, Liu B, Luo D-J, Liu D, et al. Glycogen synthase kinase-3? regulates Tyr307 phosphorylation of protein phosphatase-2A via protein tyrosine phosphatase 1B but not Src. Biochem J. 2011; 437: 335–44. https://doi.org/10.1042/BJ20110347 PMID: 21554241
41. Buus S, Rockberg J, Forsström B, Nilsson P, Uhlen M, Schafer-Nielsen C. High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays. Mol Cell Proteomics. 2012; 11: 1790–800. https://doi.org/10.1074/mcp.M112.020800 PMID: 22984286